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technique, such as the one presented in
Eq. (1), should be used.
Figure 2 shows the same reflectance
measurements of Figure 1 after correct-
ing for the detector dark current and for
the light source spectrum. The spectra
shown in Figure 2 closely resemble
previously published data (Takiwaki
et al., 2004; Matts et al., 2007) taken
with different instrumentation setups.
In summary, RS can be used as a
diagnostic aid in dermatology if proper
correction and normalization techni-
ques are employed.
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TO THE EDITOR
The author is correct in his statement that
appropriate use of a reflectance spectro-
photometer requires an instrument setup
with 100% transmission standards (white)
and 0% transmission standards (black or
dark current). Indeed, as stated in the
Materials and Methods section, these
standards, as well as Labsphere ISO
9901-certified reflectance standards red,
green, yellow, and blue, and neutral
color standards 20, 50, and 99% trans-
mission standards were evaluated in the
study exam each day before the evalua-
tion of a human being, and repeated
every 2hours throughout each study
session to insure optimal instrument
quality assurance. Values for all standards
demonstrated temporal variability of less
than 10% in a dedicated study exam
room with no windows, and controlled
ambient temperature (23±21C) and re-
lative humidity (25–30%). To our knowl-
edge, such quality assurance methods
have neither been incorporated nor been
validated in earlier studies.
The novelty of the current reflec-
tance spectrophotometer method to
establish a skin phototype compared
with previously published methods is
the use of a single and readily acces-
sible photo-protected skin site at the
upper volar arm to establish a baseline
skin color. Although a photo-exposed
site is often used to assess the ability of
skin to ‘‘tan’’ or quantify UVR exposure
history, it was not used in the current
studies to establish skin phototype
owing to its demonstrated seasonal
dependence.
The instrument light source noted by
Gonza´lez, as well as spectral digitizing
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Figure 2. Reflectance measurements after correcting for detector dark current and for the light source
spectrum.
Abbreviations: ISO, international organization for standardization; UVR, ultraviolet radiation
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software, room temperature, ambient
light conditions, and probe angle may
influence the reflectance spectral values.
Thus, all reflectance spectrophotometers
should be independently validated in
appropriate and known Fitzpatrick skin
types under the environmental and
investigator conditions of assessment to
establish the mathematical-fitted equa-
tion between subjective and objective
skin phototype. Given that the same light
source was utilized throughout the stu-
dies, and reflected light spectra of
commercial color and light/dark stan-
dards were validated daily, normaliza-
tion of the reflectance spectral data with
the dark current (0% transmission) and
light source spectrum before each sub-
ject was not necessary for an accurate
skin phototype assessment. Normaliza-
tion methods may be useful, however,
when comparison between instruments,
light sources, investigators, or study
locations is desired.
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TO THE EDITOR
Although the pathogenesis of the majo-
rity of chronic idiopathic urticaria
(CIU) patients is unknown, approxi-
mately 40% of patients are proposed
to have ‘‘functional’’ IgG autoantibo-
dies against either the high-affinity IgE
receptor (FceRIa) or IgE as measured by
the basophil histamine-releasing activ-
ity (HRA) assay (Ferrer and Kaplan,
2007). This assay involves incubating
basophils from a healthy donor with a
CIU patient’s serum and measuring
histamine release. A ‘‘positive’’ result
is often judged in relation to basophil
HRA levels obtained with serum from a
non-CIU population. Some investiga-
tors have proposed that the presence of
‘‘functional’’ autoantibodies offers a
pathogenic explanation for patients’
symptoms or provides a rationale for
treatment with immunomodulatory
therapy such as cyclosporine (Sabroe
and Greaves, 2006). However, the HRA
assay, which is considered the ‘‘gold
standard’’ (Ferrer and Kaplan, 2007) for
‘‘functional’’ autoantibodies, has limita-
tions. Its performance depends on the
unique characteristics of the healthy
basophil donors (Eckman et al., 2008).
In addition, interlaboratory reproduci-
bility of this test has not been possible
to assess because of a lack of univer-
sally available standardized reagents.
An alternative line of investigation
has shown that basophils from active
CIU subjects manifest a suppressed IgE
receptor-mediated histamine degranu-
lation (Ferrer and Kaplan, 2007). We
have stratified CIU subjects into
responder (CIU R) and nonresponder
(CIU NR) functional phenotypes based
on the profile of ex vivo activation of
their basophils by an optimal concen-
tration (0.1 mgml1) of polyclonal anti-
IgE (Vonakis et al., 2007). Subjects with
o10% histamine release with anti-IgE
stimulation were classified as CIU NR,
whereas subjects with histamine release
X10% were classified as CIU R. This
basophil classification remains consis-
tent over the course of active disease
(Eckman et al., 2008). Interestingly,
increased basophil IgE-receptor-
mediated histamine release occurs in
both groups as subjects enter disease
remission (Eckman et al., 2008). Using
a previously identified immunoenzy-
mometric assay (IEMA), we observed a
similar prevalence and concentration of
IEMA-detected autoantibodies in the
CIU R, CIU NR, and non-CIU subject
groups (Eckman et al., 2008). We have
previously reported that positive HRA
presence occurs at a similar frequency
in CIU R, CIU NR, and nonatopic,
healthy (normal) subjects (Vonakis
et al., 2007). The positive HRA results
we obtained in the non-CIU subjects
have been challenged (Kaplan and
Joseph, 2007).
The purpose of this study was to
assess HRA activity in sera from CIU
and non-CIU subjects by the CU Index
test by IBT Laboratories (Lenexa, KS).
Further, we examined the relationship
of HRA activity to previously deter-
mined CIU basophil classification and
the presence of IEMA-detected autoan-
tibodies.
Following consent, whole-blood
was collected for basophil and serology
studies from subjects with a physician-
determined diagnosis of CIU (n¼ 21) or
non-CIU controls (n¼22; ages 18–65,
12 female, 10 male, 9 atopic, 13
nonatopic by history). None of the
non-CIU subjects had any known auto-
immune disease. Protocols were
approved by the Johns Hopkins Institu-
tional Review Board and the Western
Institutional Review Board and were in
adherence to the Declaration of
Helsinki Principles (Eckman et al.,
2008). Basophil functional phenotyping
studies were performed as described
Abbreviations: CIU NR, CIU non-responder; CIU R, CIU responder; CIU, Chronic idiopathic urticaria;
HRA, Histamine release activity; IEMA, Immunoenzymetric assay
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